Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 11/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.40 |
| ▸ | HTR1A | P08908 | 7/20 | 0.39 |
| ▸ | HTR7 | P34969 | 7/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.38 |
| ▸ | MTOR | P42345 | 5/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26808816 | 1.00 | PIK3CG (0.40) | PIK3CGPIK3CDPIK3CBHTR1AHTR7 | |
| SCHEMBL26811485 | 0.91 | PIK3CG (0.39) | PIK3CGPIK3CDPIK3CBHTR1AHTR7 | |
| SCHEMBL24309827 | 0.83 | HTR1A (0.43) | PIK3CGPIK3CDPIK3CBHTR1AHTR7 | |
| SCHEMBL29566900 | 0.83 | HTR1A (0.43) | PIK3CGPIK3CDPIK3CBHTR1AHTR7 | |
| SCHEMBL29567228 | 0.82 | HTR1A (0.40) | PIK3CGPIK3CDPIK3CBHTR1AHTR7 | |
| SCHEMBL24309861 | 0.82 | HTR1A (0.40) | PIK3CGPIK3CDPIK3CBHTR1AHTR7 | |
| SCHEMBL24309799 | 0.82 | CYP2C9 (0.32) | PIK3CGPIK3CDPIK3CB | |
| SCHEMBL24310419 | 0.79 | HTR1A (0.39) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL29567143 | 0.79 | HTR1A (0.39) | HTR1AHTR7DRD2HTR6HTR2A | |
| SCHEMBL24309774 | 0.79 | HTR1A (0.34) | PIK3CGPIK3CDPIK3CBHTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PIK3CG 533/4885PIK3CD 368/4885PIK3CB 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.